Why the study?
Do maternally derived circulating antibodies mitigate clinical disease following rotavirus infection in neonatal swine?
Do maternally derived circulating antibodies mitigate clinical disease following rotavirus infection in neonatal swine?
High titers of circulating maternally derived antibodies significantly mitigate clinical disease severity following rotavirus infection in neonatal swine.
Answers are grounded in this paper and cite their sources.
Supports maternal antibody strategies in swine models; leaves open translation to other species or clinical rotavirus management.
The ability of maternally derived antibodies in the circulation of neonatal pigs to protect against challenge with virulent porcine group A rotavirus (OSU strain) was evaluated. Groups of neonatal pigs with nondetectable (group 1), low (group 2), or high (group 3) serum levels of OSU rotavirus-specific maternally derived antibodies were challenged with virulent OSU rotavirus at 3 days of age and monitored for infection and disease. Control pigs were sham-inoculated with diluent at 3 days of age. Although all virus-inoculated pigs shed rotavirus and developed diarrhea, group 3 pigs developed significantly less severe diarrhea and shed for significantly fewer days than group 1 and 2 pigs, and they maintained appetites and weight gains comparable to sham-inoculated controls. It was concluded that circulating maternally derived antibodies play a significant role in mitigating clinical disease following rotavirus infection in neonatal swine and that the protection afforded by these antibodies is titer dependent.
No takes yet. Share an insight, caveat, or question.
Ward et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: